FibroGen, Inc. (FGEN)

NASDAQ: FGEN · Delayed Price · USD
8.41
-0.79 (-8.59%)
At close: May 18, 2022 4:00 PM
8.80
0.39 (4.64%)
Pre-market:May 19, 2022 7:10 AM EDT
Market Cap784.63M
Revenue (ttm)257.71M
Net Income (ttm)-281.47M
Shares Out93.30M
EPS (ttm)-3.14
PE Ration/a
Forward PE61.35
Dividendn/a
Ex-Dividend Daten/a
Volume853,569
Open8.93
Previous Close9.20
Day's Range8.22 - 9.11
52-Week Range7.81 - 30.13
Beta0.79
AnalystsSell
Price Target13.67 (+62.5%)
Earnings DateMay 9, 2022

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human mon...

IndustryBiotechnology
IPO DateNov 14, 2014
CEOEnrique Conterno
Employees566
Stock ExchangeNASDAQ
Ticker SymbolFGEN
Full Company Profile

Financial Performance

In 2021, FibroGen's revenue was $235.31 million, an increase of 33.46% compared to the previous year's $176.32 million. Losses were -$290.02 million, 53.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for FGEN stock is "Sell." The 12-month stock price forecast is 13.67, which is an increase of 62.54% from the latest price.

Price Target
$13.67
(62.54% upside)
Analyst Consensus: Sell
Stock Forecasts

News

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

FibroGen Reports First Quarter 2022 Financial Results

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company's recent developments.

1 week ago - GlobeNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating FibroGen, Inc.

Wilmington, Delaware--(Newsfile Corp. - May 5, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockholders...

1 week ago - Newsfile Corp

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigat...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigatio...

1 week ago - Business Wire

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

FibroGen to Report First Quarter 2022 Financial Results

SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct...

3 weeks ago - GlobeNewsWire

FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2021 and provided an update on the company's recent d...

2 months ago - GlobeNewsWire

Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroG...

3 months ago - GlobeNewsWire

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th...

3 months ago - GlobeNewsWire

FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright ...

4 months ago - GlobeNewsWire

FibroGen Exercises Exclusive License Option for HiFiBiO's CCR8 Program

SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class thera...

4 months ago - GlobeNewsWire

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of Long-Term Stockholders and E...

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fibrogen, Inc. (NASDAQ: FGEN) on behalf of...

5 months ago - Business Wire

FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

FibroGen Reports Third Quarter 2021 Financial Results

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2021 and provided an update on the Company's recent developments.

6 months ago - GlobeNewsWire

FibroGen to Present at Upcoming Investor Conferences

SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following health...

6 months ago - GlobeNewsWire

FibroGen to Report Third Quarter 2021 Financial Results

SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also co...

6 months ago - GlobeNewsWire

FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Societ...

6 months ago - GlobeNewsWire

What's Happening With FibroGen Stock?

Last month, we discussed that FibroGen (NASDAQ: FGEN) stock price could rebound over a one-month period after falling 6% in a week, based on the Trefis Machine Learning Engine. However, FGEN stock has s...

7 months ago - Forbes

Why FibroGen Fell by More Than 9% on Wednesday

A noted investment bank takes a dimmer view of the company's stock.

7 months ago - The Motley Fool

Will FibroGen Stock Rebound After Positive Roxadustat Data?

The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a large sell-off in FGEN stock, ...

8 months ago - Forbes

FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study

FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.

8 months ago - Zacks Investment Research

FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial

FibroGen Inc (NASDAQ: FGEN) has announced topline data from WHITNEY Phase 2 study of roxadustat for chemotherapy-induced anemia (CIA). The trial met the primary efficacy endpoint of maximum change in he...

8 months ago - Benzinga